Latest Insider Transactions at Kala Pharmaceuticals, Inc. (KALA)
This section provides a real-time view of insider transactions for Kala Pharmaceuticals, Inc. (KALA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kala Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kala Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2022
|
Mark T Iwicki |
SELL
Open market or private sale
|
Direct |
7,975
-3.08%
|
$0
$0.37 P/Share
|
|
Jun 27
2022
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
3,092
-2.61%
|
$0
$0.37 P/Share
|
|
Jun 27
2022
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
3,144
-1.09%
|
$0
$0.37 P/Share
|
|
Jun 27
2022
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,613
-1.96%
|
$0
$0.37 P/Share
|
|
Jun 27
2022
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
2,613
-2.3%
|
$0
$0.37 P/Share
|
|
May 26
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,005,686
-12.5%
|
$0
$0.36 P/Share
|
|
May 25
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,434,509
-15.13%
|
$0
$0.42 P/Share
|
|
May 24
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
144,805
-1.5%
|
$0
$0.51 P/Share
|
|
May 23
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,250,000
-11.49%
|
$0
$0.65 P/Share
|
|
Feb 15
2022
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Other acquisition or disposition
|
Direct |
9
-0.06%
|
-
|
|
Jan 04
2022
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
2,850
-2.44%
|
$2,850
$1.3 P/Share
|
|
Jan 04
2022
|
Mark T Iwicki |
SELL
Open market or private sale
|
Direct |
9,518
-3.54%
|
$9,518
$1.3 P/Share
|
|
Jan 04
2022
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
3,454
-2.83%
|
$3,454
$1.3 P/Share
|
|
Jan 04
2022
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
3,504
-1.2%
|
$3,504
$1.3 P/Share
|
|
Jan 04
2022
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,850
-2.09%
|
$2,850
$1.3 P/Share
|
|
Nov 15
2021
|
Mark S. Blumenkranz |
BUY
Grant, award, or other acquisition
|
Indirect |
5,183,355
+50.0%
|
-
|
|
Nov 15
2021
|
Mark S. Blumenkranz |
BUY
Grant, award, or other acquisition
|
Direct |
157,765
+50.0%
|
-
|
|
Nov 15
2021
|
Darius Kharabi CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
295,657
+50.0%
|
-
|
|
Oct 27
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
21,051
-9.33%
|
$21,051
$1.82 P/Share
|
|
Oct 26
2021
|
Mark T Iwicki |
SELL
Open market or private sale
|
Direct |
27,598
-9.32%
|
$27,598
$1.8 P/Share
|
|
Oct 26
2021
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
12,757
-4.19%
|
$12,757
$1.8 P/Share
|
|
Oct 26
2021
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
12,544
-9.32%
|
$12,544
$1.8 P/Share
|
|
Oct 26
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,449
-6.49%
|
$9,449
$1.8 P/Share
|
|
Oct 26
2021
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
9,449
-7.49%
|
$9,449
$1.8 P/Share
|
|
Oct 26
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
9,449
-4.02%
|
$9,449
$1.8 P/Share
|
|
Jun 29
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
5,548
-2.31%
|
$27,740
$5.56 P/Share
|
|
Jun 28
2021
|
Mark T Iwicki |
SELL
Open market or private sale
|
Direct |
7,586
-2.5%
|
$37,930
$5.77 P/Share
|
|
Jun 28
2021
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
2,911
-2.12%
|
$14,555
$5.77 P/Share
|
|
Jun 28
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,452
-1.66%
|
$12,260
$5.77 P/Share
|
|
Jun 28
2021
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
2,452
-1.91%
|
$12,260
$5.77 P/Share
|
|
Jun 28
2021
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
3,034
-1.0%
|
$15,170
$5.77 P/Share
|
|
Jun 28
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,452
-1.01%
|
$12,260
$5.77 P/Share
|
|
Jun 17
2021
|
Gregory Grunberg |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Andrew I Koven |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+32.05%
|
-
|
|
Jun 17
2021
|
Robert Bradley Paull |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Gregory D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Howard B Rosen |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+30.85%
|
-
|
|
Jun 17
2021
|
Rajeev M. Shah |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Apr 01
2021
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,687,709
+30.86%
|
$10,126,254
$6.74 P/Share
|
|
Mar 01
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+3.76%
|
$19,000
$2.3 P/Share
|
|
Feb 25
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
47,000
+16.75%
|
$94,000
$2.3 P/Share
|
|
Jan 04
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+13.28%
|
-
|
|
Jan 04
2021
|
Mark T Iwicki |
BUY
Grant, award, or other acquisition
|
Direct |
76,000
+20.01%
|
-
|
|
Jan 04
2021
|
Todd Bazemore |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+16.67%
|
-
|
|
Jan 04
2021
|
Eric Trachtenberg |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+14.99%
|
-
|
|
Jan 04
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+10.84%
|
-
|
|
Jan 04
2021
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+8.3%
|
-
|
|
Oct 26
2020
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+32.74%
|
-
|
|
Oct 26
2020
|
Mark T Iwicki |
BUY
Grant, award, or other acquisition
|
Direct |
178,300
+43.9%
|
-
|
|
Oct 26
2020
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+22.66%
|
-
|